The Filing Desk

Arvinas vs Iovance Biotherapeutics

Arvinas ARVN · Iovance Biotherapeutics IOVA · Biotechnology

Iovance Biotherapeutics reported revenue of $264 million in fiscal 2025, about the same as Arvinas' $263 million in fiscal 2025. Arvinas' revenue fell 0.3% in its latest year, and Iovance Biotherapeutics' grew 60.6%. Arvinas had an operating margin of -45.1%, against -153.1% at Iovance Biotherapeutics. Free cash flow was −$276 million at Arvinas and −$336 million at Iovance Biotherapeutics.

Side by side

ArvinasIovance Biotherapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$263M$264M
Revenue growth−0.3%60.6%
Revenue growth a year, last 5 years58.9%—
Gross margin—34.3%
Operating margin−45.1%−153.1%
Net margin−30.8%−148.4%
Free cash flow−$276M−$336M
Free cash flow margin−105.0%−127.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$92M$0M
Change in diluted share count−1.4%23.3%
Last close$6.82$7.76
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score5 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ArvinasIovance Biotherapeutics
Operating margin
Percent of revenue
ArvinasIovance Biotherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArvinasIovance Biotherapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arvinas and Iovance Biotherapeutics pages.